Tumor-infiltrating CCR2⁺ inflammatory monocytes counteract specific immunotherapy.

ABSTRACT: Tumor development and progression is shaped by the tumor microenvironment (TME), a heterogeneous assembly of infiltrating and resident host cells, their secreted mediators and intercellular matrix. In this context, tumors are infiltrated by various immune cells with either pro-tumoral or anti-tumoral functions. Recently, we published our non-invasive immunization platform DIVA suitable as a therapeutic vaccination method, further optimized by repeated application (DIVA²). In our present work, we revealed the therapeutic effect of DIVA² in an MC38 tumor model and specifically focused on the mechanisms induced in the TME after immunization. DIVA² resulted in transient tumor control followed by an immune evasion phase within three weeks after the initial tumor

SUBMITTER: Bartneck J 

PROVIDER: S-EPMC10577317 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature